Exelixis, Inc. EXEL today announced the pricing of its
underwritten public offering of 25,000,000 shares of newly issued common
stock at a price to the public of $5.40 per share. The gross proceeds to
Exelixis from this offering are expected to be approximately $135
million, before deducting the underwriting discount and other estimated
offering expenses payable by Exelixis. Exelixis also granted the
underwriters a 30-day option to purchase up to an additional 3,750,000
shares of its common stock. All of the shares are being sold by Exelixis.
Exelixis currently expects to use the net proceeds from the offerings
for general corporate purposes, including for clinical trials, build-out
of commercial infrastructure, research and development, capital
See full press release
Market News and Data brought to you by Benzinga APIs© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Loading...
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in